T. Foukakis, K. Wang, I. Zerdes, Y. Zhu, E. Sifakis, N. Tsiknakis, G. Manikis, D. Salgkamis, L. Harbers, J. Bergh, H. Johansson, N. Crosetto, J. Lehtiö, A. Matikas, T. Hatschek
{"title":"多组学分析揭示了 HER2 阳性乳腺癌患者对新辅助抗体药物共轭物与化疗和双重 HER2 阻断剂反应的预测性分子特征","authors":"T. Foukakis, K. Wang, I. Zerdes, Y. Zhu, E. Sifakis, N. Tsiknakis, G. Manikis, D. Salgkamis, L. Harbers, J. Bergh, H. Johansson, N. Crosetto, J. Lehtiö, A. Matikas, T. Hatschek","doi":"10.1016/j.ejca.2024.113830","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":505596,"journal":{"name":"European Journal of Cancer","volume":"224 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multiomic profiling reveals predictive molecular characteristics of response to neoadjuvant antibody-drug conjugate versus chemotherapy and dual HER2 blockade in HER2 positive breast cancer\",\"authors\":\"T. Foukakis, K. Wang, I. Zerdes, Y. Zhu, E. Sifakis, N. Tsiknakis, G. Manikis, D. Salgkamis, L. Harbers, J. Bergh, H. Johansson, N. Crosetto, J. Lehtiö, A. Matikas, T. Hatschek\",\"doi\":\"10.1016/j.ejca.2024.113830\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":505596,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\"224 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ejca.2024.113830\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ejca.2024.113830","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Multiomic profiling reveals predictive molecular characteristics of response to neoadjuvant antibody-drug conjugate versus chemotherapy and dual HER2 blockade in HER2 positive breast cancer